Skip to main content
Signal8
Smith W Bradford profile photo

W. Bradford Smith

CIK: 0001317678

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (50.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Lyra Therapeutics, Inc. logo
LYRA

Lyra Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (2 total)

  • Lyra Therapeutics, Inc. logo
    LYRA

    Lyra Therapeutics, Inc.

    May 14, 2026
    Disposition(D)
    Direct
    640 shares-
  • Lyra Therapeutics, Inc. logo
    LYRA

    Lyra Therapeutics, Inc.

    May 14, 2025
    Award(A)

    Restricted Stock Units

    Direct
    32K shares-

1-2 of 2

W. Bradford Smith files insider reports with the SEC as Director of Lyra Therapeutics, Inc. (LYRA). Signal8 holds 2 reported Form 4/5 transactions by W. Bradford Smith since Sep 2024. The most recent reported transaction is a disposition to issuer (Form 4 code D) in LYRA, dated May 14, 2026.

About Smith W Bradford

Smith W Bradford (SEC CIK 0001317678) files insider reports with the SEC as Director of Lyra Therapeutics, Inc. (LYRA).

Signal8 holds 2 ownership filings by Smith W Bradford, all Form 4s, filed between May 16, 2025 and May 15, 2026. Those filings report 2 transactions, from May 14, 2025 to May 14, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Smith W Bradford's filings is in WATERTOWN, MA.

Recent filings by Smith W Bradford

  • May 14, 2026: Disposition to issuer transaction of LYRA shares (Form 4, code D).
  • May 14, 2025: Grant or award of LYRA derivative securities (Form 4, code A).

Other insiders filing for Lyra Therapeutics, Inc. (LYRA)

How to read Form 4 transaction codes